About EnteroMedics (NASDAQ:ETRM)
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ETRM
- CUSIP: 29365M20
- Web: www.enteromedics.com
- Market Cap: $16.67 million
- Outstanding Shares: 14,565,000
- 50 Day Moving Avg: $1.88
- 200 Day Moving Avg: $3.84
- 52 Week Range: $1.60 - $30.41
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.14
- P/E Growth: -5.71
- Annual Revenue: $571,759.00
- Price / Sales: 51.20
- Book Value: $4.58 per share
- Price / Book: 0.44
- EBITDA: ($22,150,000.00)
- Net Margins: -4,399.48%
- Return on Equity: -167.73%
- Return on Assets: -123.00%
- Current Ratio: 2.95%
- Quick Ratio: 2.63%
- Average Volume: 742,155 shs.
- Beta: 3.07
- Short Ratio: 5.33
Frequently Asked Questions for EnteroMedics (NASDAQ:ETRM)
What is EnteroMedics' stock symbol?
EnteroMedics trades on the NASDAQ under the ticker symbol "ETRM."
When did EnteroMedics' stock split? How did EnteroMedics' stock split work?
Shares of EnteroMedics reverse split on the morning of Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.
How were EnteroMedics' earnings last quarter?
EnteroMedics Inc. (NASDAQ:ETRM) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.09. The firm earned $0.09 million during the quarter, compared to analyst estimates of $0.20 million. EnteroMedics had a negative return on equity of 167.73% and a negative net margin of 4,399.48%. View EnteroMedics' Earnings History.
When will EnteroMedics make its next earnings announcement?
Where is EnteroMedics' stock going? Where will EnteroMedics' stock price be in 2017?
1 brokerages have issued 1-year target prices for EnteroMedics' stock. Their forecasts range from $11.00 to $11.06. On average, they expect EnteroMedics' stock price to reach $11.03 in the next twelve months. View Analyst Ratings for EnteroMedics.
Who are some of EnteroMedics' key competitors?
Some companies that are related to EnteroMedics include Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT), Dynatronics Corporation (DYNT), PhotoMedex (PHMD), Dextera Surgical (DXTR), Alliance HealthCare Services (AIQ), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI), Hansen Medical (HNSN), Lifeline Scientific (LSIC), Mindray Medical International Ltd (MR), Nanosphere (NSPH), Sirona Dental Systems (SIRO), Sphere Medical Holding PLC (SPHR), Synergetics USA (SURG), Thoratec (THOR) and Volcano Corp (VOLC).
Who are EnteroMedics' key executives?
EnteroMedics' management team includes the folowing people:
- Dan W. Gladney, Chairman of the Board, President, Chief Executive Officer
- Scott P. Youngstrom, Chief Financial Officer, Chief Compliance Officer
- Naqeeb Ansari, Senior Vice President - Sales
- Paul Hickey, Senior Vice President - Marketing and Reimbursement
- Peter M. Delange, Senior Vice President - Operations and Business Development
- Adrianus Donders, Senior Vice President - Research and Advanced Development
- Katherine S. Tweden Ph.D., Senior Vice President - Research
- Tonya Dowd, Vice President - Reimbursement
- Gary D. Blackford, Director
- Lori Courtney McDougal, Director
How do I buy EnteroMedics stock?
Shares of EnteroMedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EnteroMedics' stock price today?
MarketBeat Community Rating for EnteroMedics (NASDAQ ETRM)MarketBeat's community ratings are surveys of what our community members think about EnteroMedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of EnteroMedics stock can currently be purchased for approximately $2.01.
Earnings History for EnteroMedics (NASDAQ:ETRM)Earnings History by Quarter for EnteroMedics (NASDAQ ETRM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|8/8/2017||Q2 2017||($1.00)||($0.91)||$0.20 million||$0.09 million||View||Listen|
|5/16/2017||Q1 2017||($0.63)||($1.27)||$0.04 million||View||N/A|
|3/7/2017||Q4 2016||($0.44)||($2.65)||$0.14 million||View||N/A|
|11/10/2016||Q3 2016||($0.50)||($0.17)||$0.34 million||$0.30 million||View||N/A|
|8/4/2016||Q216||($0.75)||($0.49)||$0.19 million||$0.28 million||View||N/A|
|2/17/2016||Q315||($0.90)||($0.95)||$0.43 million||$0.15 million||View||Listen|
|8/6/2015||Q215||($0.10)||($0.10)||$0.06 million||$0.08 million||View||N/A|
|5/1/2013||Q1 2013||($0.13)||($0.14)||$0.10 million||View||N/A|
|2/13/2013||Q4 2012||($0.14)||($0.17)||$0.36 million||View||N/A|
Earnings Estimates for EnteroMedics (NASDAQ:ETRM)
Current Year EPS Consensus Estimate: $-1.40 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
Dividend History for EnteroMedics (NASDAQ:ETRM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for EnteroMedics (NASDAQ:ETRM)
Insider Ownership Percentage: 32.50%Insider Trades by Quarter for EnteroMedics (NASDAQ:ETRM)
Institutional Ownership Percentage: 0.89%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/25/2017||Carl Goldfischer||Director||Sell||4,668||$4.85||$22,639.80|| |
|6/3/2016||Peter M Delange||SVP||Buy||20,000||$0.55||$11,000.00|| |
|8/13/2015||Mark B Knudson||CEO||Buy||303,000||$0.25||$75,750.00|| |
|6/19/2014||Cathy Friedman||Director||Buy||11,800||$1.70||$20,060.00|| |
|1/8/2014||Luke Evnin||Director||Sell||556,585||$2.50||$1,391,462.50|| |
|2/27/2013||Anthony P Jansz||Director||Buy||150,000||$0.95||$142,500.00|| |
Headline Trends for EnteroMedics (NASDAQ:ETRM)
Latest Headlines for EnteroMedics (NASDAQ:ETRM)
EnteroMedics (ETRM) Chart for Wednesday, October, 18, 2017